| Breast Cancer |
1 |
0.95 |
| Revenue and Practice Management |
0 |
0.87 |
| Cancer |
0 |
0.81 |
| Advanced and Metastatic Breast Cancer |
0 |
0.71 |
| Biologic Therapy |
0 |
0.7 |
| Antineoplastic Drug |
0 |
0.61 |
| Medicare |
0 |
1 |
| Salary and Compensation |
0 |
0.22 |
| Breast |
0 |
0.18 |
| Face |
0 |
0.15 |
| Epidermal Growth Factor Receptor |
0 |
0.08 |
| Drug Costs |
0 |
0.07 |
| Health Plans |
0 |
0.07 |
| Health Policy |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Aromatase Inhibitors |
0 |
0.04 |
| Cost Sharing |
0 |
0.04 |
| Grant |
0 |
0.04 |
| Hand |
0 |
0.04 |
| Health Care Cost |
0 |
0.04 |
| Humanized Monoclonal Antibody |
0 |
0.04 |
| Leukemia |
0 |
0.04 |
| Lymphoma |
0 |
0.04 |
| Prescription Drugs |
0 |
0.04 |
| Retirement |
0 |
0.04 |
| Taxane |
0 |
0.04 |